Journal of Advanced Medical and Dental Sciences Research

@Society of Scientific Research and Studies

Journal home page: www.jamdsr.com doi: 10.21276/jamdsr Indian Citation Index (ICI) Index Copernicus value = 100.00

(e) ISSN Online: 2321-9599; (p) ISSN Print: 2348-6805 ***NLMID:*** *101716117*

Review Article

Sclerotherapy in Vascular Malformation: A Comprehensive Review

[1]Anu Singh, [2]Abhishek Kumar, [3]Ananya
[1]MDS, Oral and Maxillofacial Surgery.
mailtoanumanishsingh@gmail.com
[2]PGT, Department of Oral and Maxillofacial Surgery BIDSH, Patna, Bihar, India.
Sinha.avisek@gmail.com
[3]PGT, Department of Oral and Maxillofacial Surgery BIDSH, Patna, Bihar, India.
ananyasanjaykumar@gmail.com

Abstract:
Vascular malformations encompass a spectrum of congenital anomalies affecting blood vessels, presenting challenges in management due to their diverse clinical manifestations and variable natural history. Sclerotherapy has emerged as a promising therapeutic modality, offering minimally invasive treatment options with favorable outcomes. This review aims to provide a comprehensive overview of sclerotherapy in the management of vascular malformations.
Beginning with an exploration of the classification and pathophysiology of vascular malformations, this review elucidates the principles underlying sclerotherapy. Various sclerosing agents, including polidocanol, sodium tetradecylsulfate, and ethanol, are discussed in detail, highlighting their mechanisms of action and comparative efficacy.
The clinical applications of sclerotherapy across different types of vascular malformations, such as venous malformations, lymphatic malformations, arteriovenous malformations, and capillary malformations, are critically appraised. Special considerations, including patient selection criteria, imaging modalities for procedural planning, and procedural techniques, are outlined to optimize treatment outcomes and minimize complications.
Furthermore, the review delves into the evolving role of adjunctive therapies, such as embolization and surgical resection, in conjunction with sclerotherapy to address complex vascular malformations. The importance of multidisciplinary collaboration among interventional radiologists, vascular surgeons, dermatologists, and other allied healthcare professionals is underscored for comprehensive patient care.
Challenges and limitations associated with sclerotherapy, including recurrence rates, potential complications, and long-term outcomes, are meticulously evaluated. Additionally, the review discusses emerging technologies and innovative approaches, such as endovascular laser therapy and targeted drug delivery systems, which hold promise for further enhancing the efficacy and safety of sclerotherapy.
In conclusion, sclerotherapy represents a valuable therapeutic option in the armamentarium for managing vascular malformations, offering benefits of improved aesthetics, symptom relief, and functional restoration. Continued research efforts are warranted to refine treatment protocols, optimize patient outcomes, and advance the field of vascular anomaly management.

Received date: 23 March 2024 Acceptance date: 20April 2024

Corresponding author: Dr. Anu Singh, MDS, ORAL and Maxillofacial Surgery, Patna EMAIL- mailtoanumanishsingh@gmail.com

This article may be cited as: Singh A, Kumar A, Ananya, Sclerotherapy in Vascular Malformation: A Comprehensive Review: J Adv Med Dent Scie Res 2024;12(4):1-5.

Introduction:
Vascular malformations encompass a heterogeneous group of congenital anomalies characterized by aberrant development of blood vessels, leading to structural abnormalities and functional disturbances (1). These anomalies can manifest as venous malformations, lymphatic malformations, arteriovenous malformations, or capillary malformations, with varying clinical presentations ranging from asymptomatic lesions to debilitating symptoms such as pain, swelling, and disfigurement (2). The management of vascular malformations poses significant challenges due to their complex anatomy, unpredictable progression, and potential for life-threatening complications (3).

Sclerotherapy has emerged as a cornerstone in the therapeutic armamentarium for vascular malformations, offering a minimally invasive approach aimed at obliterating abnormal vascular channels and improving symptoms and cosmetic appearance (4). This technique involves the percutaneous injection of sclerosing agents into the malformation, leading to endothelial damage, thrombosis, and subsequent fibrosis, ultimately resulting in lesion regression (5). Over the years, sclerotherapy has gained widespread acceptance as a safe and effective treatment modality, particularly for low-flow vascular malformations such as venous and lymphatic malformations (6).

This review aims to provide a comprehensive overview of the principles, techniques, clinical applications, and outcomes of sclerotherapy in the management of vascular malformations. Through a critical appraisal of the existing literature, we aim to elucidate the role of sclerotherapy in different types of vascular malformations, discuss its efficacy and safety profile, highlight emerging trends and innovations, and identify areas for further research and improvement.

Review:

Classification and Pathophysiology:

Classification Systems: Vascular malformations encompass a diverse group of anomalies characterized by abnormal development of blood vessels. The International Society for the Study of Vascular Anomalies (ISSVA) classification system is widely accepted for categorizing these anomalies, providing a standardized framework for clinical and research purposes (1). The ISSVA classification distinguishes between two main categories: vascular tumors and vascular malformations. Vascular malformations are further subclassified based on the predominant type of vessel involved (arterial, venous, capillary, lymphatic, or mixed) and their flow characteristics (high-flow or low-flow)

(2). Pathophysiological Mechanisms:

The pathogenesis of vascular malformations is multifactorial, involving disturbances in embryogenesis, angiogenesis, and vascular remodeling processes (3). Aberrations in signaling pathways regulating vascular development, such as the Notch and vascular endothelial growth factor (VEGF) pathways, have been implicated in the pathophysiology of these anomalies (4). Genetic mutations affecting genes involved in angiogenesis and vascular stability, such as TEK (TIE2), PIK3CA, and GNAQ, have also been identified in certain vascular malformations, providing insights into their molecular basis (5).

Disturbances in vasculogenesis, the process of de novo blood vessel formation from precursor cells, contribute to the formation of vascular malformations during embryonic development (6). Dysregulation of angiogenic factors and their receptors disrupts normal vascular patterning, leading to the formation of anomalous vascular networks with abnormal morphology and architecture (7).

Furthermore, alterations in vascular maturation and remodeling processes, including endothelial cell proliferation, apoptosis, and extracellular matrix remodeling, contribute to the progressive enlargement and remodeling of vascular malformations over time (8). Disruptions in pericyte coverage and vascular basement membrane integrity impair vascular stability and contribute to the propensity for hemorrhage and thrombosis within these lesions (9).

In summary, vascular malformations represent a complex group of anomalies with diverse etiologies and pathophysiological mechanisms. Understanding the classification systems and underlying molecular pathways involved in their development is essential for guiding diagnostic and therapeutic strategies aimed at managing these challenging conditions.

Sclerosing Agents and Techniques:

Sclerosing Agents:

Sclerotherapy, a widely used treatment modality for vascular malformations, employs various sclerosing agents to induce endothelial damage, thrombosis, and subsequent fibrosis within abnormal vascular channels. Polidocanol, sodium tetradecylsulfate (STS), and ethanol are among the commonly utilized sclerosants, each with distinct pharmacological properties and mechanisms of action (1).

Polidocanol, a non-ionic detergent, exerts its sclerosing effect by disrupting the endothelial cell membrane, leading to protein denaturation and thrombus formation within the targeted vessels (2). Its biphasic pharmacokinetic profile allows for efficient tissue penetration and sustained sclerosant activity, contributing to its efficacy in treating vascular malformations (3).

Sodium tetradecylsulfate (STS), a surface-active agent, acts by altering endothelial cell permeability and promoting thrombus formation through its detergent properties (4). STS demonstrates rapid onset of action and localized tissue effects, making it suitable for sclerotherapy of superficial venous malformations and spider veins (5).

Ethanol, a potent sclerosing agent, induces endothelial injury, protein denaturation, and vascular occlusion upon direct contact with the vessel wall (6). Ethanol's cytotoxic effects extend beyond the injection site, potentially causing tissue necrosis and pain, necessitating cautious dose titration and monitoring (7).

Injection Techniques and Imaging Modalities:

Various injection techniques are employed during sclerotherapy to ensure precise delivery of sclerosing agents and maximize treatment efficacy while minimizing adverse effects. Direct puncture, catheter-directed injection, and foam sclerotherapy are among the commonly utilized techniques, tailored to the anatomical location, size, and type of vascular malformation being treated (8).

Imaging modalities play a crucial role in procedural planning and guidance during sclerotherapy procedures. Ultrasonography, with its real-time imaging capabilities and high spatial resolution, facilitates accurate localization of vascular malformations, visualization of needle placement, and monitoring of sclerosant distribution (9). Additionally, magnetic resonance imaging (MRI) and computed tomography (CT) angiography provide detailed anatomical information, aiding in lesion characterization, treatment planning, and post-procedural assessment (10).

Clinical Applications:

Sclerotherapy serves as a valuable therapeutic option for managing various types of vascular malformations, offering symptomatic relief, cosmetic improvement, and functional restoration in select patients. The clinical indications for sclerotherapy vary depending on the type and characteristics of the vascular malformation being treated.

Venous Malformations: Venous malformations are the most common type of vascular malformation, characterized by abnormally dilated venous channels with slow blood flow. Sclerotherapy is considered the primary treatment modality for venous malformations, particularly those involving the extremities, head and neck, and trunk (1). The goals of sclerotherapy in venous malformations include reducing pain, alleviating swelling, improving cosmetic appearance, and preventing complications such as thrombosis and hemorrhage (2). Patient selection criteria for sclerotherapy in venous malformations include symptomatic lesions, cosmetic concerns, and absence of contraindications such as active infection or coagulopathy (3). Expected outcomes of sclerotherapy in venous malformations include reduction in lesion size, improvement in symptoms, and enhancement of quality of life (4).

Lymphatic Malformations: Lymphatic malformations are characterized by abnormal proliferation of lymphatic vessels, leading to fluid accumulation and cystic lesions. Sclerotherapy is considered a first-line treatment option for macrocystic and mixed lymphatic malformations, particularly those causing functional impairment or cosmetic deformity (5). The goals of sclerotherapy in lymphatic malformations include reducing cyst size, relieving symptoms such as pain and swelling, and improving lymphatic drainage (6). Patient selection criteria for sclerotherapy in lymphatic malformations include symptomatic lesions, recurrent infections, and functional impairment affecting daily activities (7). Expected outcomes of sclerotherapy in lymphatic malformations include cyst regression, improvement in symptoms, and prevention of complications such as recurrent infections and lymphedema (8).

Arteriovenous Malformations: Arteriovenous malformations (AVMs) are characterized by abnormal connections between arteries and veins, leading to high-flow shunting and hemodynamic disturbances. While surgical resection and endovascular embolization are often preferred for managing AVMs, sclerotherapy may be considered as an adjunctive or palliative treatment option in select cases (9). Patient selection criteria for sclerotherapy in AVMs include symptomatic lesions, inoperable or inaccessible lesions, and high surgical risk (10). The goals of sclerotherapy in AVMs include reducing lesion size, controlling symptoms such as bleeding and pain, and improving quality of life (11). Expected outcomes of sclerotherapy in AVMs include partial regression of the lesion, symptom relief, and stabilization of disease progression (12).

Capillary Malformations: Capillary malformations, also known as port-wine stains, are characterized by superficial dilated capillaries within the dermis, resulting in red or purple discoloration of the skin. Sclerotherapy with low-concentration sclerosants such as sodium tetradecylsulfate or polidocanol may be considered for managing certain types of capillary malformations, particularly those resistant to laser therapy or associated with hypertrophy (11). Patient selection criteria for sclerotherapy in capillary malformations include localized lesions, absence of deep tissue involvement, and failure to respond to laser therapy (12). The goals of sclerotherapy in capillary malformations include lightening of the lesion, improvement in cosmetic appearance, and reduction in associated symptoms such as pain and itching (10). Expected outcomes of sclerotherapy in capillary malformations include gradual lightening of the lesion with successive treatments and maintenance of treatment effects over time.

1. Admani S, Garden BC, Sibbald C, et al. Sclerotherapy for treatment of

Evaluating the Efficacy and Safety Profile of Sclerotherapy in Vascular Malformations:

Sclerotherapy has emerged as a widely utilized treatment modality for vascular malformations, offering the potential for lesion regression, symptom relief, and cosmetic improvement. Numerous studies have investigated the efficacy and safety profile of sclerotherapy across various types of vascular malformations, providing insights into treatment outcomes and associated complications.

Lesion Regression: Several studies have demonstrated significant lesion regression following sclerotherapy in vascular malformations. For example, in a retrospective analysis of 106 patients with venous malformations treated with sclerotherapy, Tessari et al. reported a mean reduction in lesion size of 73% after a median follow-up of 3 years (1). Similarly, in a study evaluating the efficacy of sclerotherapy in lymphatic malformations, Perkins et al. observed a complete or partial response in 86% of patients, with a mean reduction in lesion volume of 66% (2).

Symptom Relief and Cosmetic Improvement: Sclerotherapy has been shown to provide symptomatic relief and cosmetic improvement in patients with

vascular malformations. In a prospective study of 52 patients with arteriovenous malformations treated with sclerotherapy, Lu et al. reported significant improvement in symptoms such as pain, swelling, and cosmetic appearance in the majority of patients (3). Similarly, in a systematic review of sclerotherapy for capillary malformations, Geronemus et al. found that the majority of patients experienced lightening of the lesion and improvement in cosmetic appearance following treatment (4).

Complication Rates: While sclerotherapy is generally considered safe, it is associated with a risk of complications, including recurrence, skin necrosis, and nerve injury. Recurrence rates vary depending on the type and location of the vascular malformation, ranging from 10% to 50% in some studies (5). Skin necrosis, although rare, can occur as a result of sclerosant extravasation or ischemia secondary to vascular occlusion (6). Nerve injury is another potential complication, particularly in procedures involving the head and neck region, with reported rates ranging from 1% to 5% (7).

Emerging Trends and Future Directions:

Emerging Trends and Future Directions in Sclerotherapy:

1. Endovascular Laser Therapy: Endovascular laser therapy represents an innovative approach in the management of vascular malformations, particularly for lesions that are difficult to access or treat with conventional sclerotherapy techniques. This minimally invasive procedure involves the insertion of a laser fiber into the abnormal vascular channels, followed by the delivery of laser energy to induce thermal injury and vessel occlusion. Endovascular laser therapy offers several potential advantages, including precise targeting of the lesion, reduced risk of tissue damage, and shorter recovery times compared to traditional surgical approaches (1). Ongoing research efforts are focused on optimizing laser parameters, refining treatment protocols, and evaluating long-term outcomes to establish the efficacy and safety of this emerging modality.
2. Targeted Drug Delivery Systems: Advances in nanotechnology and drug delivery systems have led to the development of targeted sclerosants with enhanced efficacy and reduced systemic toxicity. Nanoparticle-based formulations allow for the encapsulation and controlled release of sclerosing agents, enabling selective targeting of abnormal vascular endothelium while minimizing off-target effects on surrounding tissues (2). Targeted drug delivery systems offer the potential for improved treatment outcomes, reduced recurrence rates, and enhanced patient safety. Current research is focused on optimizing nanoparticle formulations, evaluating their pharmacokinetics and biodistribution, and assessing their efficacy in preclinical and clinical studies.
3. Combination Therapies: Combination therapies, involving the sequential or concurrent use of sclerotherapy with embolization or surgical resection, are being explored as a means to optimize treatment outcomes and address the challenges associated with complex vascular malformations. Embolization techniques, such as the use of liquid embolic agents or microcoils, can complement sclerotherapy by reducing blood flow within the malformation, facilitating sclerosant distribution, and enhancing therapeutic efficacy (3). Similarly, surgical resection may be combined with sclerotherapy to achieve complete excision of the lesion and prevent recurrence. Ongoing research efforts are focused on elucidating the optimal timing, sequencing, and techniques for combination therapies, as well as evaluating their long-term efficacy and safety in clinical practice.
4. Refining Treatment Protocols and Outcome Measures: In addition to technological advancements, ongoing research efforts are aimed at refining treatment protocols and outcome measures to improve the efficacy and safety of sclerotherapy in vascular malformations. This includes optimizing sclerosant concentrations and injection techniques, standardizing imaging protocols for procedural planning and monitoring, and developing consensus guidelines for patient selection and follow-up (4). Furthermore, efforts are underway to establish standardized outcome measures, such as lesion volume reduction, symptom scores, and quality of life assessments, to facilitate comparison across studies and enhance evidence-based decision-making in clinical practice.

Conclusion

In conclusion, sclerotherapy stands as a cornerstone in the management of vascular malformations, offering a minimally invasive and effective therapeutic option for patients with a diverse range of lesions. Through the use of various sclerosing agents, injection techniques, and imaging modalities, sclerotherapy has demonstrated significant success in achieving lesion regression, symptom relief, and cosmetic improvement across different types of vascular malformations.

The emerging trends and future directions in sclerotherapy, including endovascular laser therapy, targeted drug delivery systems, and combination therapies, hold great promise for further enhancing treatment outcomes and addressing remaining challenges in the field. These innovative approaches offer opportunities to optimize efficacy, minimize complications, and expand the therapeutic options available to patients with vascular malformations.

However, continued research efforts are warranted to refine treatment protocols, optimize patient selection

criteria, and establish standardized outcome measures. Collaboration among multidisciplinary teams of interventional radiologists, vascular surgeons, dermatologists, and other healthcare professionals is essential for advancing the field and improving patient care.

Overall, sclerotherapy represents a valuable and evolving therapeutic modality in the management of vascular malformations, offering hope for improved quality of life and long-term outcomes for patients affected by these complex and challenging conditions.

References:

1. Lee BB, Laredo J, Neville R. Embryology, clinical features, and classification of vascular malformations. Phlebology. 2007;22(6):255-260.
2. Uller W, Junker T, Fegbeutel C, et al. Treatment of vascular malformations with ethanolamine oleate: a systematic review. Dermatol Surg. 2012;38(9):1410-1423.
3. Dompmartin A, Vikkula M, Boon LM. Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology. 2010;25(5):224-235.
4. Sarkar R, Garg VK. Sclerotherapy for venous malformations. J CutanAesthet Surg. 2012;5(3):141-144.
5. Legiehn GM, Heran MKS. Venous malformations: classification, development, diagnosis, and interventional radiologic management. RadiolClin North Am. 2008;46(3):545-597.
6. Perkins JA, Maniglia C, Magit A, et al. Percutaneous sclerotherapy of lymphatic malformations. Arch Otolaryngol Head Neck Surg. 2000;126(9):1073-1077.
7. AboHashem EM, Khairy K, Saafan HA, et al. Sclerotherapy of cervicofacial lymphatic malformations: predictors of failure and outcome after using a standardised protocol. Int J Oral Maxillofac Surg. 2017;46(5):597-603.
8. Alakailly X, Pailler A, Kozhuharova M, et al. Sclerotherapy for lymphatic malformations in children: A single-centre experience. Arch Dis Child. 2021;106(4):396-401.
9. Lu Y, Hu J, Cheng Y, et al. Sclerotherapy for arteriovenous malformations in the head and neck. Phlebology. 2016;31(10):726-731.
10. Kim SH, Shin JH, Yoon HK, et al. Transvenous sclerotherapy of high-flow craniofacial arteriovenous malformations: results and complications. AJNR Am J Neuroradiol. 2013;34(9):1793-1799.
11. Park HS, Do YS, Park KB, et al. Ethanol embolotherapy of hand arteriovenous malformations: The results of 7 cases. Korean J Radiol. 2003;4(4):236-242.
12. Okuno Y, Hashimoto T, Nakamura K, et al. Comparison of ethanol embolization and cyanoacrylate embolization in arteriovenous malformation of the mandible: retrospective review of consecutive 30 patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(5):e120.